業績一覧
ACHIEVEMENT LIST
-
Mäkitie AA, Alabi RO, Orell H, Youssef O, Almangush A, Homma A, Takes RP, López F, de Bree R, Rodrigo JP, Ferlito A. Managing Cachexia in Head and Neck Cancer: a Systematic Scoping Review.
Adv Ther. 39:1502-1523, 2022
-
Matsumoto-Sasaki M, Simizu K, Suzuki M, Suzuki M, Kimura H, Nakamaru Y, Ito YM, Honma A(Homma A), Konno S.：Clinical Characteristics of Patients and Factors Associated with Switching Biologics in Asthma.
J Asthma Allergy 15：187-195, 2022
-
Nakagawa J, Fujima N, Hirata K, Tang M, Tsuneta S, Suzuki J, Harada T, Ikebe Y, Homma A, Kano S, Minowa K, Kudo K：Utility of the deep learning technique for the diagnosis of orbital invasion on CT in patients with a nasal or sinonasal tumor.
Cancer Imaging. 22(1): 52, 2022
-
Ota Y, Kodaira T, Fujii H, Shimokawa M, Yokota T, Nakashima T, Monden N, Homma A, Ueda S, Akimoto T : Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2).
Int J Clin Oncol. 27(11): 1675-1683, 2022
-
Saito Y, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ota I, Yokota T, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Okano S, Imamura Y, Ariizumi Y, Hayashi R: Human papillomavirus-related oropharyngeal carcinoma.
Jpn J Clin Oncol. 52(7):692-698, 2022
-
Yasumatsu R, Shimizu Y, Hanai N, Kariya S, Yokota T, Fujii T, Tsukahara K, Ando M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Yonekura S, Asakage T, Nekado T, Yamada T, Homma A.: Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study.
Int J Clin Oncol. 27:95-104, 2022
-
Wang J, Wang N, Zheng Z, Che Y, Suzuki M, Kano S, Lu J, Wang P, Sun Y, Homma A： Exosomal lncRNA HOTAIR induce macrophages to M2 polarization via PI3K/ p-AKT /AKT pathway and promote EMT and metastasis in laryngeal squamous cell carcinoma.
BMC Cancer. 22 :1208, 2022
-
Kawakita D, Nagao T, Takahashi H, Kano S, Honma Y, Hirai H, Saigusa N, Akazawa K, Tani K, Ojiri H, Tsukahara K, Ozawa H, Okami K, Kondo T, Togashi T, Fushimi C, Shimura T, Shimizu A, Okamoto I, Okada T, Imanishi Y, Watanabe Y, Otsuka K, Sakai A, Ebisumoto K, Sato Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Ando M, Matsuki T, Nakaguro M, Sato Y, Urano M, Utsumi Y, Kohsaka S, Saotome T, Tada Y: Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Ther Adv Med Oncol. 14:17588359221119538, 2022
-
Kohsaka S, Tada Y, Ando M, Nakaguro M, Shirai Y, Ueno T, Kojima S, Hirai H, Saigusa N, Kano S, Tsukahara K, Togashi T, Ozawa H, Kondo T, Okami K, Takahashi H, Kawakita D, Fushimi C, Suzuki T, Shimizu A, Okamoto I, Okada T, Sato Y, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Urano M, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Shimura T, Nagao T, Mano H: Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.
NPJ Precis Oncol. 6(1):82, 2022
-
Nakano S, Okumura Y, Murase T, Nagao T, Kusafuka K, Urano M, Yamamoto H, Kano S, Tsukahara K, Okami K, Kawakita D, Nagao T, Hanai N, Iwai H, Kawata R, Tada Y, Nibu KI, Inagaki H : Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Ther Adv Med Oncol. 14:17588359221119538, 2022